Physician profile
Lisa Johnson
NPI 1982060497
$3,395.47
in general payments reported to CMS, 2019-2025
19 companies · $2,929 in 2025
The $2,929 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2023: $19.86 · 2024: $324 · 2025: $2,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,273.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $492.52 | 2025 | Tavneos, Krystexxa |
| Teva Pharmaceuticals USA, INC. | $381.45 | 2025 | |
| Axsome Therapeutics, INC. | $326.78 | 2025 | Auvelity, Symbravo |
| Alexion Pharmaceuticals, INC. | $252.83 | 2025 | |
| Neurocrine Biosciences, INC. | $248.88 | 2024-2025 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $236.29 | 2025 | Voquezna |
| Sage Therapeutics, LLC | $195.17 | 2025 | |
| Organogenesis INC. | $174.09 | 2025 | Apligraf |
| Dexcom, INC. | $135.37 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Genzyme Corporation | $130.00 | 2021-2023 | |
| Hologic Sales and Service, LLC | $118.51 | 2025 | Aptima |
| Springworks Therapeutics, INC. | $118.33 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $102.82 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $97.32 | 2025 | Neffy |
| Emd Serono, INC. | $95.58 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $95.40 | 2025 | Wegovy |
| Sumitomo Pharma America, INC. | $94.50 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $87.56 | 2025 | Spravato |
| Alkermes, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.